Ischemic priapism induced by a fixed drug combination of tamsulosin and tadalafil

Libin Sanjeev Leonson; Vimal Dixit; Annwesha Chaudhury; Ayush Jain; Shikha Dwivedi

doi:10.18203/2319-2003.ijbcp20250492

Authors

Libin Sanjeev Leonson Department of Pharmacology, Government Doon Medical College, Dehradun, Uttarakhand, India
Vimal Dixit Department of Urology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, India
Annwesha Chaudhury Department of Pharmacology, Government Doon Medical College, Dehradun, Uttarakhand, India
Ayush Jain Department of Pharmacology, Government Doon Medical College, Dehradun, Uttarakhand, India
Shikha Dwivedi Department of Pharmacology, Government Doon Medical College, Dehradun, Uttarakhand, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20250492

Keywords:

Priapism, Tamsulosin, Tadalafil

Abstract

Priapism, a persistent erection lasting more than 4 hours, can be caused by various factors, including medications. This case report presents a 23-year-old male who developed ischemic priapism after taking tablet Contiflo-T, a combination of tamsulosin and tadalafil. The patient required multiple interventions, including aspiration and intracavernosal phenylephrine injections, to resolve the condition. The combination of these drugs, which are commonly used for urinary tract symptoms and erectile dysfunction, likely contributed to the priapism by increasing blood flow to the penis and preventing its return to a flaccid state. This case highlights the potential for adverse drug interactions and the importance of careful monitoring when prescribing medications for these conditions.

Metrics

Metrics Loading ...

References

Melman A, Serels S. Priapism. Int J Impot Res. 2000;12(S4):S133-9. DOI: https://doi.org/10.1038/sj.ijir.3900592

Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JPW, Lue TF, et al. American urological association guideline on the management of priapism. J Urol. 2003;170(4 Part 1):1318-24. DOI: https://doi.org/10.1097/01.ju.0000087608.07371.ca

El‐Bahnasawy MS, Dawood A, Farouk A. Low‐flow priapism: risk factors for erectile dysfunction. BJU Int. 2002;89(3):285-90. DOI: https://doi.org/10.1046/j.1464-4096.2001.01510.x

Lui JL, Shaw NM, Abbasi B, Hakam N, Breyer BN. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database. Andrology. 2023;11(7):1408-17. DOI: https://doi.org/10.1111/andr.13430

Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors? J Sexual Med. 2020;17(8):1579-82. DOI: https://doi.org/10.1016/j.jsxm.2020.05.019